To this end, in our previous reports, we demonstrated modest or no clinical responses in HLA-A*02:01+ PCa patients vaccinated with a modified HER-2/neu polypeptide, although these patients exhibited strong preexisting immunity to a variety of PCa-associated peptides [38,39]. The gene discussed is HLA-A; the disease is posterior cortical atrophy.